Trial Profile
A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms DELTA
- Sponsors Gilead Sciences
- 01 May 2021 Results assessing final efficacy and safety data published in the Leukemia and Lymphoma
- 01 Apr 2021 Results of a post hoc analysis of data pooled from 2 trials (NCT01539512 and NCT01282424) assessing the degree of comorbidity burden and the impact of Idelalisib on bleeding events published in the Leukemia and Lymphoma
- 21 Jun 2020 Results (N=408), pooled analysis of 4 studies assessing efficacy of Idelalisib in patients with indolent non Hodgkins lymphoma and CLL, presented at the 25th Congress of the European Haematology Association